Figure 1: Structural Formula Of Liraglutide (49f302f5 F315 48b8 83a4 6ca56f01fded 01)
Victoza Injection
Product Images NDC 0169-4060
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Victoza (NDC 0169-4060). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novo Nordisk, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 Mean Insulin Secretion Rate (isr) Versus Glucose Concentration (49f302f5 F315 48b8 83a4 6ca56f01fded 02)
Figure 4 Mean Hba1c For Patients Who Completed The 26-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 26 (49f302f5 F315 48b8 83a4 6ca56f01fded 04)
Victoza Pen And Needle (Image 01)
This seems to be a visual guide or diagram for the Victoza pen, showing the different parts and components of the device, such as the rubber cartridge tip, stopper, display, and needle. The text also provides a phone number and website for troubleshooting assistance.*
Figure: Pull Off Pen Cap (Image 02)
Figure: Attaching Needle (Image 03)
Figure: Remove Outer Needle Cap (Image 04)
Figure: Remove Inner Needle Cap (Image 05)
Figure: Turn Dose Selector To Flow Check Symbol (Image 06)
Figure: Tap Cartridge Gently With Finger (Image 07)
Figure: Keep Needle Pointing Up And Press Dose Button (Image 08)
Figure: Pull Off Pen Cap (Image 09)
Figure: Attaching Needle (Image 10)
Figure: Remove Outer Needle Cap (Image 11)
Figure: Remove Inner Needle Cap (Image 12)
Figure: Turn Dose Selector To Dose (Image 13)
Figure: 0.6 mg, 1.2 mg And 1.8 mg Dose (Image 14)
Figure: Delivering The Dose (Image 15)
Keep Dose Button Pressed Down For 6 Seconds. (Image 16)
Figure: Withdraw The Needle (Image 17)
Figure: Safely Remove The Needle (Image 18)
Figure 5 (Image 20)
The text describes a comparison between the drug Victoza and a placebo over a course of 54 months in a full analysis set. The data includes the number of patients at risk for each treatment at different time points. The HR (hazard ratio) is given as 0.87 with a 95% CI (confidence interval) of 0.78 to 0.97.*
Figure 3 (Image 21)
This is a graph comparison between Glimepiride and VICTOZA 1.2mg over time (weeks) with an additional comparison of VICTOZA 1.8mg. The values obtained are significant, with a p-value less than 0.0001 for VICTOZA 1.8mg compared to both Glimepiride and VICTOZA 1.2mg. ANCOVA was used to analyze the data.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
